The clinical performance of CMT2A is complex and often involves multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of CMT2A requires a combination of clinical performance, imaging, laboratory testing and pathological evaluation.
The platform can assist in bringing together a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. The treatment and management of CMT2A requires the individualization of treatment programs, typically including multiple-dimensional management, including drug therapy, rehabilitation prevention, and regular follow-up. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many of the neural system disorders that have previously been difficult to treat have improved significantly.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of CMT2A. The platform serves a team of domestic and foreign experts in the field of neural systems related to the China International Medical Service System, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.